Claims for Patent: 9,663,581

Summary for Patent: 9,663,581

Title:	Modified glycoproteins
Abstract:	Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.
Inventor(s):	Washburn; Nathaniel (Littleton, MA), Meador, III; James (Framingham, MA), Bosques; Carlos J. (Arlington, MA), Bulik; Dorota A. (Malden, MA), Bhatnagar; Naveen (Framingham, MA), Brown; Julia (Somerville, MA), Markowitz; Lynn (Waltham, MA), Prabbhakar; Sathya (Boxborough, MA)
Assignee:	Momenta Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	14/396,420
Patent Claims:	1. A preparation comprising a glycoprotein comprising a modified amino acid sequence of a reference glycoprotein, the reference glycoprotein comprising an immunoglobulin Fc region or Fc fragment; wherein the glycoprotein of the preparation comprises an Fc region comprising two amino acid substitutions relative to the Fc region or Fc fragment of the reference glycoprotein, and wherein the two amino acid substitutions are selected from the group consisting of F241A/F243A, F241A/K246A, F241A/T260A, F241A/R301A, F243A/K246A, F243A/T260A, F243A/R301A, K246A/T260A, K246A/R301A, and T260A/R301A, as numbered according to the EU numbering index of Kabat, and wherein the preparation of the glycoprotein has an increased level of one or more of sialylated glycans, fucosylated glycans, and N-acetylglucosamine glycans, relative to a preparation of the reference glycoprotein. 2. The preparation of claim 1, wherein the glycoprotein of the preparation has a different Fc receptor affinity, Fc receptor specificity, complement activation activity, signaling activity, targeting activity, effector function, half-life, clearance, anti-inflammatory activity, or transcytosis activity than the reference glycoprotein. 3. The preparation of claim 2, wherein the effector function is antibody dependent cellular cytotoxicity, complement dependent cytotoxicity, programmed cell death, or cellular phagocytosis. 4. The preparation of claim 2, wherein the glycoprotein of the preparation has a different Fc receptor affinity or Fc receptor specificity than the reference glycoprotein, wherein the Fc receptor is an Fc.gamma.RT, Fc.gamma.RIIA, Fc.gamma.RIIB, Fc.gamma.RIIIA, Fc.gamma.RIIIB, Fc.gamma.RIV, or FcRn receptor. 5. The preparation of claim 4, wherein the glycoprotein of the preparation binds to a macrophage, neutrophil, or eosinophil. 6. The preparation of claim 1, wherein the reference glycoprotein is an antibody. 7. The preparation of claim 6, wherein the antibody is abciximab, adalimumab, alemtuzumab, basiliximab, bevacizumab, cetuximab, certolizumab, daclizumab, eculizumab, efalizumab, gemtuzumab, ibritumomab, infliximab, muromonab, natalizumab, omalizumab, palivizumab, panitumumab, ranibizumab, rituximab, tositumomab, or trastuzumab. 8. The preparation of claim 1, wherein the preparation of the glycoprotein comprises an increased level of sialylated glycans relative to a preparation of the reference glycoprotein. 9. The preparation of claim 1, wherein the preparation of the glycoprotein comprises an increased level of fucosylated glycans relative to a preparation of the reference glycoprotein. 10. The preparation of claim 1, wherein the preparation of the glycoprotein comprises an increased level of N-acetylglucosamine glycans relative to a preparation of the reference glycoprotein. 11. The preparation of claim 8, wherein the level of sialylated glycans is increased by 10% to 500% relative to a preparation of the reference glycoprotein. 12. The preparation of claim 9, wherein the level of fucosylated glycans is increased by 10% to 500% relative to a preparation of the reference glycoprotein. 13. The preparation of claim 10, wherein the level of N-acetylglucosamine glycans is increased by 10% to 500% relative to a preparation of the reference glycoprotein. 14. The preparation of claim 1, wherein the glycoprotein of the preparation comprises two Fc regions, wherein one of the Fc regions comprises two amino acid substitutions selected from the group consisting of F241A/F243A, F241A/K246A, F241A/T260A, F241A/R301A, F243A/K246A, F243A/T260A, F243A/R301A, K246A/T260A, K246A/R301A, and T260A/R301A relative to the Fc region or Fc fragment of the reference glycoprotein, as numbered according to the EU numbering index of Kabat. 15. The preparation of claim 1, wherein the glycoprotein of the preparation comprises two Fc regions, wherein the two Fc regions comprise two amino acid substitutions selected from the group consisting of F241A/F243A, F241A/K246A, F241A/T260A, F241A/R301A, F243A/K246A, F243A/T260A, F243A/R301A, K246A/T260A, K246A/R301A, and T260A/R301A relative to the Fc region or Fc fragment of the reference glycoprotein, as numbered according to the EU numbering index of Kabat.

Details for Patent 9,663,581

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2032-04-25
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2032-04-25
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2032-04-25
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2032-04-25